Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN001 in Patients With Sarcopenia
NCT07808905Phase 2Not yet recruiting
- Sponsor
- ENCell
- Start
- Mar 2027
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EN001 in Sarcopenia (6 arms), sponsored by ENCell. Primary endpoints: Dose Limiting Toxicity at 12 weeks and Short Physical Performance Battery at 24 weeks. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
EN001
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT07808905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808905.